Format

Send to

Choose Destination
Horm Metab Res Suppl. 1992;26:50-1.

Efficacy of 6 months monotherapy with glucosidase inhibitor Acarbose versus sulphonylurea glibenclamide on metabolic control of dietary treated type II diabetics (NIDDM).

Author information

1
Bayer AG, Institute for Clinical Research II, Wuppertal, Germany.

Abstract

Six months monotherapy with Acarbose vs. glibenclamide led to a marked improvement of BG and HbA1 in NIDDM, insufficiently controlled with diet. Beneficial effects of these distinct principles of action were statistically not different.

PMID:
1490692
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center